-
Research Groups
Clinical Research
-
Reading Group
Patrick’s group investigates how the body first detects and responds to respiratory viruses. They investigate viral attachment factors, cellular receptors and entry pathways, virus-induced activation of host genes and the mechanisms by which intracellular host proteins can block virus replication.
Other work areas include:COVID-19, Immunology, Viral Infectious Diseases
Current Projects
-
Identifying cell-surface attachment factors and entry receptors for respiratory viruses
In addition to influenza A virus (IAV), members of the Paramyxoviridae family cause significant respiratory disease in humans. These include mumps virus (MuV), human metapneumovirus (HMPV) and respiratory syncytial virus (RSV) and parainfluenza viruses (PIV). Many respiratory viruses use cell-surface glycans (such as sialic acid and glycosaminoglycans) as attachment factors to concentrate virions at the cell surface, however little is known regarding the specific receptors utilised by these viruses to enter host cells. Patrick’s group uses a range of molecular, biochemical and virological approaches to identify specific cell surface virus receptors to characterise how they recognise and internalise viruses.
-
Identifying novel antiviral genes and understanding how they block influenza virus infection
Alveolar macrophages are susceptible to seasonal IAV infection but block virus growth whereas monocyte-derived macrophages and airway epithelial cells support virus growth. Therefore, alveolar macrophages express (unknown) host factors that block seasonal IAV. Of interest, highly pathogenic avian influenza (HPAI) H5N1 does grow in alveolar macrophages and therefore evades restriction factors that block seasonal IAV. In Patrick’s laboratory, they are developing experimental approaches to examine individual host genes to assess their ability to block the growth of seasonal IAV. Moreover, they are investigating the viral determinants of HPAI H5N1 that allow them to evade these host restriction factors.
Lab Team
-
Melkamu TessemaPhD student
-
Lara SchwabPhD student
-
Harry StannardMasters student
-
Fernando Villalon LetelierPhD student
-
Brown Group
Lorena’s group is dedicated to understanding different aspects of influenza virus structure and replication, as well as the host immune response to the virus that may impact on disease outcome. They study areas of vulnerability that can be targeted by vaccines and therapeutics to control seasonal and highly pathogenic isolates.
-
Deng Group
While her team’s core task has always been on the molecular surveillance of influenza viruses and its methodology development, Yi-Mo’s group have been collaborating actively both within and outside the Centre on several research projects relating to the molecular characterisation and evolution of human or animal influenza viruses.
-
Hurt Group
Aeron’s research team at the WHO Collaborating Centre for Reference and Research on Influenza works on aspects of understanding the replication and transmission of drug resistant influenza viruses, characterising novel drug resistance mutations, and the global movement and evolution of human and avian influenza viruses.
-
Kedzierska Group
Professor Katherine Kedzierska’s team researches immunity to viral infections, especially the newly emerged SARS-CoV-2 and influenza viruses. Her work spans basic research from mouse experiments to human immunity through to clinical settings, with particular focus on understanding universal CD8+ T cell immunity to respiratory viruses. Her studies aim to identify key correlates of severe and fatal respiratory disease in high-risk groups including children, the elderly, Australian First Nations people, pregnant women and patients with co-morbidities.
Other work areas include:COVID-19, Immunology, Viral Infectious Diseases
-
Kent Group
Stephen’s group studies immunity to HIV, influenza and SARS-CoV-2. They are analysing a variety of vaccine strategies, including nanoparticle-based vaccines. They are studying a series of immune responses to gain better insights into protective immunity to important viral pathogens. They are developing monoclonal antibody therapies for HIV, influenza and SARS-CoV-2 to improve the treatment of these infections. The Kent group works very closely with Dr Amy Chung’s laboratory at the Doherty Institute.
Other work areas include:COVID-19, Immunology, HIV
-
Sullivan Group
Sheena’s epidemiology group at the WHO Collaborating Centre for Reference and Research on Influenza undertakes research into understanding influenza vaccine effectiveness and the validity of the methods used to estimate it. The group also provides technical assistance to partners in the Western Pacific Region of the WHO.
Other work areas include:COVID-19, Immunology, Viral Infectious Diseases
-
Valkenburg Lab
The Valkenburg laboratory investigates viral immunity to emerging viruses with pandemic potential: influenza viruses and SARS-CoV-2. Our work spans randomised control vaccine trials, observational studies of infected patients and animal models to decipher immune correlates to drive novel translational outcomes for specific diagnostics, targeted therapeutics and next generation vaccines for public health impact.
Other work areas include:COVID-19, Immunology, Viral Infectious Diseases, Public Health
-
Wakim Group
Linda’s group’s main research focus is understating the mechanism of action and regulation of expression of antiviral proteins. Linda’s group also aims to characterise CD8 T cell responses within the lung following virus infection.
Other work areas include:Immunology
Anyone can be infected by influenza, but some people are more susceptible to infection, severe disease and clinical complications. Clinical studies at the Doherty Institute are focused on specific risk groups, seeking to understand characteristics of viruses and the immune system that result in increased susceptibility and clinical severity. In particular, current studies are considering:
- Young children and the elderly in collaboration with Deepdene Surgery
- Indigenous Australians in collaboration with Griffith University, Queensland
- High-risk groups of hospitalised patients in collaboration with the FluCAN network and Shanghai Public Clinical Hospital
Doherty Institute researchers are also characterising immune responses to influenza vaccination or infection in various groups of people, including:
- Health care workers in collaboration with the Peter MacCallum Cancer Centre
- Patients undergoing renal transplantations in collaboration with Monash Health
- Infants in the first year of life in collaboration with Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
Now recruiting volunteers
There are currently no Now recruiting volunteers
Current projects
-
Influenza
How do cross-reactive memory B cells affect influenza vaccine titers?
-
Influenza
LIFT: Investigating T cell immunity to influenza in Indigenous populations
-
Influenza
Understanding immunity to influenza viruses in patients hospitalised with severe and fatal disease
-
